Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dasatinib Suppresses TGFβ-Mediated Epithelial-Mesenchymal Transition in Alveolar Epithelial Cells and Inhibits Pulmonary Fibrosis.
Kanemaru R, Takahashi F, Kato M, Mitsuishi Y, Tajima K, Ihara H, Hidayat M, Wirawan A, Koinuma Y, Hayakawa D, Yagishita S, Ko R, Sato T, Harada N, Kodama Y, Nurwidya F, Sasaki S, Niwa SI, Takahashi K. Kanemaru R, et al. Among authors: hayakawa d. Lung. 2018 Oct;196(5):531-541. doi: 10.1007/s00408-018-0134-6. Epub 2018 Jun 20. Lung. 2018. PMID: 29926178
Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer.
Hidayat M, Mitsuishi Y, Takahashi F, Tajima K, Yae T, Miyahara K, Hayakawa D, Winardi W, Ihara H, Koinuma Y, Wirawan A, Nurwidya F, Kato M, Kobayashi I, Sasaki S, Takamochi K, Hayashi T, Suehara Y, Moriyama M, Moriyama H, Habu S, Takahashi K. Hidayat M, et al. Among authors: hayakawa d. Bosn J Basic Med Sci. 2019 Nov 8;19(4):355-367. doi: 10.17305/bjbms.2019.4227. Bosn J Basic Med Sci. 2019. PMID: 31202256 Free PMC article.
Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D, Takahashi F, Mitsuishi Y, Tajima K, Hidayat M, Winardi W, Ihara H, Kanamori K, Matsumoto N, Asao T, Ko R, Shukuya T, Takamochi K, Hayashi T, Suehara Y, Takeda Nakamura I, Ueno T, Kohsaka S, Mano H, Takahashi K. Hayakawa D, et al. Thorac Cancer. 2020 Jan;11(1):140-149. doi: 10.1111/1759-7714.13255. Epub 2019 Nov 22. Thorac Cancer. 2020. PMID: 31758670 Free PMC article.
Nintedanib inhibits epithelial-mesenchymal transition in A549 alveolar epithelial cells through regulation of the TGF-β/Smad pathway.
Ihara H, Mitsuishi Y, Kato M, Takahashi F, Tajima K, Hayashi T, Hidayat M, Winardi W, Wirawan A, Hayakawa D, Kanamori K, Matsumoto N, Yae T, Sato T, Sasaki S, Takamochi K, Suehara Y, Ogura D, Niwa SI, Suzuki K, Takahashi K. Ihara H, et al. Among authors: hayakawa d. Respir Investig. 2020 Jul;58(4):275-284. doi: 10.1016/j.resinv.2020.01.003. Epub 2020 Apr 29. Respir Investig. 2020. PMID: 32359980
Zinc-finger E-box-binding homeobox 1 (ZEB1) plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib.
Nurwidya F, Takahashi F, Winardi W, Tajima K, Mitsuishi Y, Murakami A, Kobayashi I, Nara T, Hashimoto M, Kato M, Hidayat M, Suina K, Hayakawa D, Asao T, Ko R, Shukuya T, Yae T, Shimada N, Yoshioka Y, Sasaki S, Takahashi K. Nurwidya F, et al. Among authors: hayakawa d. Thorac Cancer. 2021 May;12(10):1536-1548. doi: 10.1111/1759-7714.13937. Epub 2021 Mar 25. Thorac Cancer. 2021. PMID: 33764690 Free PMC article.
A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1.
Wirawan A, Tajima K, Takahashi F, Mitsuishi Y, Winardi W, Hidayat M, Hayakawa D, Matsumoto N, Izumi K, Asao T, Ko R, Shimada N, Takamochi K, Suzuki K, Abe M, Hino O, Sekido Y, Takahashi K. Wirawan A, et al. Among authors: hayakawa d. Mol Cancer Res. 2022 Jan;20(1):127-138. doi: 10.1158/1541-7786.MCR-21-0230. Epub 2021 Sep 30. Mol Cancer Res. 2022. PMID: 34593606 Free article.
Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a "tail plateau" in the survival curve of these patients?
Shimamura SS, Shukuya T, Asao T, Hayakawa D, Kurokawa K, Xu S, Miura K, Mitsuishi Y, Tajima K, Shibayama R, Shimada N, Takahashi F, Takahashi K. Shimamura SS, et al. Among authors: hayakawa d. BMC Cancer. 2022 Mar 25;22(1):323. doi: 10.1186/s12885-022-09421-7. BMC Cancer. 2022. PMID: 35337281 Free PMC article.
Anti-Müllerian hormone type II receptor protein expression in non-small cell lung cancer and the effect of AMH/AMHR2 signaling on cancer cell proliferation.
Koinuma Y, Mitsuishi Y, Winardi W, Hidayat M, Wirawan A, Hayakawa D, Kanamori K, Matsumoto N, Hayashi T, Shimada N, Tajima K, Takamochi K, Takahashi F, Suzuki K, Takahashi K. Koinuma Y, et al. Among authors: hayakawa d. Thorac Cancer. 2024 Oct;15(29):2090-2099. doi: 10.1111/1759-7714.15309. Epub 2024 Sep 4. Thorac Cancer. 2024. PMID: 39230026 Free PMC article.
165 results